Indian pharmaceutical firm Alkem Laboratories has announced to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU). The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval … This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India … read more
LinkedIn:
Alkem Laboratories